Progesterone (Synonyms: Pregn-4-ene-3,20-dione)

Name: Progesterone
Brand: MedChemExpress
SKU: HY-N0437
Rating: 5.0 (34 reviews)

Cat. No.: HY-N0437 Pureza: 99.79%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

Progesterone is a steroid hormone that regulates the menstrual cycle and is crucial for pregnancy.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 57-83-0

Tamaño	Stock	Cantidad
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	En stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	En stock	Estimated Time of Arrival: December 31
Solid
100 mg	En stock	Estimated Time of Arrival: December 31
1 g	En stock	Estimated Time of Arrival: December 31
5 g	En stock	Estimated Time of Arrival: December 31
10 g	Obtener un presupuesto
50 g	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 34 publication(s) in Google Scholar

Other Forms of Progesterone:

Progesterone-d₉ In-stock
Progesterone-¹³C₃ In-stock
Progesterone-¹³C₂ In-stock
Progesterone (Standard) In-stock
Progesterone-¹³C₅ Obtener un presupuesto

34 Publications Citing Use of MCE Progesterone

RT-PCR

IHC

In Vivo Efficacy Study

: Progesterone purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 8;15(1):8708. [Abstract]; mIL1β secretion in THP-1 cells expressed with Myc-tagged E of indicated coronaviruses in the presence of 10 μM Progesterone for 4 h.

: Progesterone purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 8;15(1):8708. [Abstract]; Co-IP using HEK293T cells with TMED10-V5 and Myc-E-MHV in the absence or presence of 10 μM Progesterone.

: Progesterone purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 8;15(1):8708. [Abstract]; Progesterone (1 mg/kg; intraperitoneal injection). IL6 mRNA levels in indicated tissues were analyzed.

: Progesterone purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 8;15(1):8708. [Abstract]; Progesterone (1 mg/kg; intraperitoneal injection). Lung inflammation was analyzed by H&E staining.

: Progesterone purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 8;15(1):8708. [Abstract]; Progesterone (1 mg/kg; intraperitoneal injection). Quantitative analysis of the area of inflammation was performed.

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas Endogenous Metabolite:

Ver todas las isoformas

Human Endogenous Metabolite Microbial Metabolite

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

Progesterone is a steroid hormone that regulates the menstrual cycle and is crucial for pregnancy.

IC₅₀ & Target

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
T47D	EC₅₀	0.1 1 Compound: P4	Activation of progesterone receptor in human T47D cells after 20 hrs by PRE-tagged luciferase reporter gene assay Activation of progesterone receptor in human T47D cells after 20 hrs by PRE-tagged luciferase reporter gene assay	[PMID: 19863083]
Breast cancer cell line	EC₅₀	18.7 3 Compound: Progesterone	Concentration that reduces difference in reversal of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50% Concentration that reduces difference in reversal of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%	[PMID: 11784143]
Breast cancer cell line	EC₅₀	18.7 3 Compound: Progesterone	Concentration that reduces difference in reversal of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50% Concentration that reduces difference in reversal of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%	[PMID: 11784143]
Breast cancer cell line	EC₅₀	18.7 3 Compound: Progesterone	Concentration that reduces difference in reversal of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50% Concentration that reduces difference in reversal of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%	[PMID: 11784143]
Breast cancer cell line	EC₅₀	22.3 3 Compound: Progesterone	Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50% Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%	[PMID: 11784143]
Breast cancer cell line	EC₅₀	22.3 3 Compound: Progesterone	Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50% Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%	[PMID: 11784143]
Breast cancer cell line	EC₅₀	22.3 3 Compound: Progesterone	Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50% Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%	[PMID: 11784143]
CHO	EC₅₀	2.77 3 Compound: 44	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
CV-1	IC₅₀	> 10000 1 Compound: Progesterone	Antagonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc assessed as effect on progesterone-induced activity by luciferase reporter gene assay Antagonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc assessed as effect on progesterone-induced activity by luciferase reporter gene assay	[PMID: 20510622]
CHO	EC₅₀	2.77 3 Compound: 44	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
T47D	EC₅₀	0.9 1 Compound: 1	Activity at progesterone receptor assessed as alkaline phosphatase activity in human T47D cells Activity at progesterone receptor assessed as alkaline phosphatase activity in human T47D cells	[PMID: 18722119]
T47D	EC₅₀	0.9 1 Compound: P4 (Progesterone)	Effective concentration on alkaline phosphatase activity in human T47D breast carcinoma cell line. Effective concentration on alkaline phosphatase activity in human T47D breast carcinoma cell line.	[PMID: 12657271]
CV-1	EC₅₀	15.2 1 Compound: Progesterone	Agonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay Agonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay	[PMID: 20510622]
CV-1	EC₅₀	2.9 1 Compound: Progesterone	Effective concentration for agonist activity towards human progesterone receptor (hPR) using the cotransfection assay in CV-1 cells Effective concentration for agonist activity towards human progesterone receptor (hPR) using the cotransfection assay in CV-1 cells	[PMID: 12781197]
T47D	EC₅₀	0.92 1 Compound: P4	Agonistic activity against progesterone receptor in alkaline phosphatase assay using human T47D breast carcinoma cell line Agonistic activity against progesterone receptor in alkaline phosphatase assay using human T47D breast carcinoma cell line	[PMID: 11859003]
Cancer cell lines	IC₅₀	27.4 3 Compound: Progesterone	Growth inhibitory activity on MDA-435/LCC6 (Pgp-positive) human breast cancer cells. Growth inhibitory activity on MDA-435/LCC6 (Pgp-positive) human breast cancer cells.	[PMID: 11784143]
CV-1	EC₅₀	2.9 1 Compound: prog	Compound was tested for agonistic activity by cotransfection assay against human Progesterone receptor in CV-1 cells Compound was tested for agonistic activity by cotransfection assay against human Progesterone receptor in CV-1 cells	[PMID: 10212133]
Cancer cell lines	IC₅₀	36.4 3 Compound: Progesterone	Growth inhibitory activity on MDA-435/LCC6-MDRI (Pgp-negative) human breast cancer cells. Growth inhibitory activity on MDA-435/LCC6-MDRI (Pgp-negative) human breast cancer cells.	[PMID: 11784143]
HEK293	EC₅₀	2 1 Compound: prog	Agonist activity at human PRGR expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at human PRGR expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 25305688]
CV-1	EC₅₀	1.5 1 Compound: progesterone	Effective concentration for half-maximal activation of human progesterone receptor expressed in CV-1 cells Effective concentration for half-maximal activation of human progesterone receptor expressed in CV-1 cells	[PMID: 9667968]
CV-1	EC₅₀	1.5 1 Compound: progesterone	Effective concentration for half-maximal activation of human progesterone receptor expressed in CV-1 cells Effective concentration for half-maximal activation of human progesterone receptor expressed in CV-1 cells	[PMID: 9667968]
HeLa	IC₅₀	> 50 6 Compound: 4	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24021891]
CV-1	EC₅₀	15.2 1 Compound: Progesterone	Agonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay Agonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay	[PMID: 20510622]
CHO	EC₅₀	2.77 3 Compound: 44	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
K562/R7	IC₅₀	10.6 3 Compound: progesterone	Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay	[PMID: 25634041]
CV-1	EC₅₀	2.89 1 Compound: Progesterone	Agonistic activity was measured for modulation of hPR-B (human progesterone receptor) in co-transfected CV-1 cells. Agonistic activity was measured for modulation of hPR-B (human progesterone receptor) in co-transfected CV-1 cells.	[PMID: 9464361]
LNCaP	IC₅₀	13.7 1 Compound: Progesterone	Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay	[PMID: 30925341]
CV-1	EC₅₀	2.9 1 Compound: Progesterone	Human progesterone receptor (hPR) agonist activity expressed in CV-1 cells Human progesterone receptor (hPR) agonist activity expressed in CV-1 cells	[PMID: 10743938]
T47D	EC₅₀	1.8 1 Compound: progesterone	Agonistic activity against human progesterone receptor in T47D breast cancer cells Agonistic activity against human progesterone receptor in T47D breast cancer cells	[PMID: 12954062]
T47D	EC₅₀	1.8 1 Compound: prog	Agonistic activity by cotransfection assay against human Progesterone receptor in T47D cells Agonistic activity by cotransfection assay against human Progesterone receptor in T47D cells	[PMID: 10212133]
T47D	EC₅₀	0.1 1 Compound: P4	Activation of progesterone receptor in human T47D cells after 20 hrs by PRE-tagged luciferase reporter gene assay Activation of progesterone receptor in human T47D cells after 20 hrs by PRE-tagged luciferase reporter gene assay	[PMID: 19863083]
CV-1	EC₅₀	2.9 1 Compound: Progesterone	Effective concentration for agonist activity towards human progesterone receptor (hPR) using the cotransfection assay in CV-1 cells Effective concentration for agonist activity towards human progesterone receptor (hPR) using the cotransfection assay in CV-1 cells	[PMID: 12781197]
T47D	EC₅₀	1.8 1 Compound: Progesterone	Human progesterone receptor (hPR) agonist activity in T47D human breast cancer cell line Human progesterone receptor (hPR) agonist activity in T47D human breast cancer cell line	[PMID: 10743938]
CV-1	EC₅₀	2.9 1 Compound: Progesterone	Agonistic activity to the human progesterone receptor (hPR)assayed in CV-1 cells in cotransfection assay. Agonistic activity to the human progesterone receptor (hPR)assayed in CV-1 cells in cotransfection assay.	[PMID: 9464360]
T47D	EC₅₀	0.92 1 Compound: P4	Agonistic activity against progesterone receptor in alkaline phosphatase assay using human T47D breast carcinoma cell line Agonistic activity against progesterone receptor in alkaline phosphatase assay using human T47D breast carcinoma cell line	[PMID: 11859003]
T47D	EC₅₀	1.8 1 Compound: prog	Agonistic activity by cotransfection assay against human Progesterone receptor in T47D cells Agonistic activity by cotransfection assay against human Progesterone receptor in T47D cells	[PMID: 10212133]
HEK293	EC₅₀	2 1 Compound: prog	Agonist activity at human PRGR expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at human PRGR expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 25305688]
CV-1	EC₅₀	2.9 1 Compound: prog	Compound was tested for agonistic activity by cotransfection assay against human Progesterone receptor in CV-1 cells Compound was tested for agonistic activity by cotransfection assay against human Progesterone receptor in CV-1 cells	[PMID: 10212133]
T47D	EC₅₀	2.2 1 Compound: progesterone	Agonist activity at human progesterone receptor in human T47D cells assessed as alkaline phosphatase activity Agonist activity at human progesterone receptor in human T47D cells assessed as alkaline phosphatase activity	[PMID: 18553958]
CV-1	EC₅₀	2.9 1 Compound: progesterone	Agonistic activity against human progesterone receptor in CV-1 cells Agonistic activity against human progesterone receptor in CV-1 cells	[PMID: 12954062]
CV-1	EC₅₀	2.9 1 Compound: progesterone	Effective concentration (EC50) against human progesterone receptor expressed in CV-1 cell Effective concentration (EC50) against human progesterone receptor expressed in CV-1 cell	[PMID: 9784110]
CV-1	EC₅₀	2.89 1 Compound: Progesterone	Agonistic activity was measured for modulation of hPR-B (human progesterone receptor) in co-transfected CV-1 cells. Agonistic activity was measured for modulation of hPR-B (human progesterone receptor) in co-transfected CV-1 cells.	[PMID: 9464361]
CV-1	EC₅₀	2.9 1 Compound: progesterone	Agonistic activity against human progesterone receptor in CV-1 cells Agonistic activity against human progesterone receptor in CV-1 cells	[PMID: 12954062]
CV-1	EC₅₀	2.9 1 Compound: Progesterone	Agonistic activity to the human progesterone receptor (hPR)assayed in CV-1 cells in cotransfection assay. Agonistic activity to the human progesterone receptor (hPR)assayed in CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	EC₅₀	2.9 1 Compound: prog	Compound was tested for agonistic activity by cotransfection assay against human Progesterone receptor in CV-1 cells Compound was tested for agonistic activity by cotransfection assay against human Progesterone receptor in CV-1 cells	[PMID: 10212133]
CV-1	EC₅₀	2.9 1 Compound: progesterone	Effective concentration (EC50) against human progesterone receptor expressed in CV-1 cell Effective concentration (EC50) against human progesterone receptor expressed in CV-1 cell	[PMID: 9784110]
CV-1	EC₅₀	2.9 1 Compound: Progesterone	Effective concentration for agonist activity towards human progesterone receptor (hPR) using the cotransfection assay in CV-1 cells Effective concentration for agonist activity towards human progesterone receptor (hPR) using the cotransfection assay in CV-1 cells	[PMID: 12781197]
CV-1	IC₅₀	14 1 Compound: Progesterone	Antagonistic activity was determined in Human mineralocorticoid receptor(hMR) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human mineralocorticoid receptor(hMR) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	EC₅₀	2.9 1 Compound: Progesterone	Human progesterone receptor (hPR) agonist activity expressed in CV-1 cells Human progesterone receptor (hPR) agonist activity expressed in CV-1 cells	[PMID: 10743938]
CV-1	IC₅₀	14 1 Compound: progesterone	Inhibitory activity (IC50) against human mineralocorticoid receptor expressed in CV-1 cells Inhibitory activity (IC50) against human mineralocorticoid receptor expressed in CV-1 cells	[PMID: 9784110]
T47D	IC₅₀	3.4 1 Compound: P4 (Progesterone)	Displacement of [3H]progesterone at progesterone receptor of T47D cells Displacement of [3H]progesterone at progesterone receptor of T47D cells	[PMID: 15081005]
T47D	IC₅₀	3.5 1 Compound: P4	Binding affinity for Progesterone receptor (PR) in human T47D breast carcinoma cells Binding affinity for Progesterone receptor (PR) in human T47D breast carcinoma cells	[PMID: 11859003]
CV-1	IC₅₀	30 1 Compound: progesterone	Inhibition of 10e-9 M aldosterone activity in CV-1 cells expressing mineralocorticoid receptor Inhibition of 10e-9 M aldosterone activity in CV-1 cells expressing mineralocorticoid receptor	[PMID: 8709117]
CV-1	IC₅₀	37 1 Compound: Progesterone	Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	IC₅₀	>10 3 Compound: Progesterone	Antagonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc assessed as effect on progesterone-induced activity by luciferase reporter gene assay Antagonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc assessed as effect on progesterone-induced activity by luciferase reporter gene assay	[PMID: 20510622]
CV-1	IC₅₀	<10 3 Compound: Progesterone	Antagonistic activity was determined in Human estrogen receptor(hER) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human estrogen receptor(hER) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	IC₅₀	37 1 Compound: progesterone	Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells	[PMID: 9784110]
CV-1	IC₅₀	>1 3 Compound: Progesterone	Antagonistic activity was determined in Human glucocorticoid receptor(hGR) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human glucocorticoid receptor(hGR) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	IC₅₀	< 10000 1 Compound: Progesterone	Antagonistic activity was determined in Human estrogen receptor(hER) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human estrogen receptor(hER) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	IC₅₀	>10 3 Compound: progesterone	IC50 determined against human estrogen receptor in CV-1 cells IC50 determined against human estrogen receptor in CV-1 cells	[PMID: 9784110]
CV-1	IC₅₀	< 10000 1 Compound: Progesterone	Antagonistic activity was determined in Human progesterone receptor(hPR) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human progesterone receptor(hPR) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	IC₅₀	>1 3 Compound: progesterone	Inhibitory activity (IC50) against human glucocorticoid receptor expressed in CV-1 cells Inhibitory activity (IC50) against human glucocorticoid receptor expressed in CV-1 cells	[PMID: 9784110]
CV-1	IC₅₀	> 1000 1 Compound: Progesterone	Antagonistic activity was determined in Human glucocorticoid receptor(hGR) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human glucocorticoid receptor(hGR) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
LNCaP	IC₅₀	13.7 1 Compound: Progesterone	Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay	[PMID: 30925341]
CV-1	IC₅₀	> 1000 1 Compound: progesterone	Inhibitory activity (IC50) against human glucocorticoid receptor expressed in CV-1 cells Inhibitory activity (IC50) against human glucocorticoid receptor expressed in CV-1 cells	[PMID: 9784110]
HEK293	IC₅₀	3.05 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT1-expressing HEK293 cells TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT1-expressing HEK293 cells	[PMID: 12110607]
CV-1	IC₅₀	> 10000 1 Compound: Progesterone	Antagonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc assessed as effect on progesterone-induced activity by luciferase reporter gene assay Antagonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc assessed as effect on progesterone-induced activity by luciferase reporter gene assay	[PMID: 20510622]
CV-1	IC₅₀	> 10000 1 Compound: progesterone	IC50 determined against human estrogen receptor in CV-1 cells IC50 determined against human estrogen receptor in CV-1 cells	[PMID: 9784110]
HEK293	IC₅₀	26.7 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT2-expressing HEK293 cells TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT2-expressing HEK293 cells	[PMID: 12110607]
CV-1	IC₅₀	> 10000 1 Compound: progesterone	inhibitory concentration was determined from full dose response curves ranging from 10 E -12 to 10 E -5M in CV-1 cell inhibitory concentration was determined from full dose response curves ranging from 10 E -12 to 10 E -5M in CV-1 cell	[PMID: 9784110]
HEK293	IC₅₀	4.28 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT3-expressing HEK293 cells TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT3-expressing HEK293 cells	[PMID: 12110607]
CV-1	IC₅₀	14 1 Compound: Progesterone	Antagonistic activity was determined in Human mineralocorticoid receptor(hMR) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human mineralocorticoid receptor(hMR) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	IC₅₀	14 1 Compound: progesterone	Inhibitory activity (IC50) against human mineralocorticoid receptor expressed in CV-1 cells Inhibitory activity (IC50) against human mineralocorticoid receptor expressed in CV-1 cells	[PMID: 9784110]
CV-1	EC₅₀	15.2 1 Compound: Progesterone	Agonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay Agonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay	[PMID: 20510622]
Cancer cell lines	IC₅₀	27.4 3 Compound: Progesterone	Growth inhibitory activity on MDA-435/LCC6 (Pgp-positive) human breast cancer cells. Growth inhibitory activity on MDA-435/LCC6 (Pgp-positive) human breast cancer cells.	[PMID: 11784143]
HeLa	IC₅₀	>50 6 Compound: 4	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24021891]
Cancer cell lines	IC₅₀	36.4 3 Compound: Progesterone	Growth inhibitory activity on MDA-435/LCC6-MDRI (Pgp-negative) human breast cancer cells. Growth inhibitory activity on MDA-435/LCC6-MDRI (Pgp-negative) human breast cancer cells.	[PMID: 11784143]
HRPE	IC₅₀	1.6 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT2-expressing HRPE cells TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT2-expressing HRPE cells	[PMID: 9830022]
HRPE	IC₅₀	10.5 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT3-expressing HRPE cells TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT3-expressing HRPE cells	[PMID: 9830022]
CV-1	IC₅₀	30 1 Compound: progesterone	Inhibition of 10e-9 M aldosterone activity in CV-1 cells expressing mineralocorticoid receptor Inhibition of 10e-9 M aldosterone activity in CV-1 cells expressing mineralocorticoid receptor	[PMID: 8709117]
HEK293	EC₅₀	2 1 Compound: prog	Agonist activity at human PRGR expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at human PRGR expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 25305688]
K562/R7	IC₅₀	10.6 3 Compound: progesterone	Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay	[PMID: 25634041]
CV-1	IC₅₀	37 1 Compound: Progesterone	Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
HEK293	IC₅₀	26.7 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT2-expressing HEK293 cells TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT2-expressing HEK293 cells	[PMID: 12110607]
CV-1	IC₅₀	37 1 Compound: progesterone	Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells	[PMID: 9784110]
HEK293	IC₅₀	3.05 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT1-expressing HEK293 cells TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT1-expressing HEK293 cells	[PMID: 12110607]
NIH-3T3-G185	IC₅₀	96.2 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells	[PMID: 11716514]
HEK293	IC₅₀	4.28 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT3-expressing HEK293 cells TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT3-expressing HEK293 cells	[PMID: 12110607]
NIH-3T3-G185	IC₅₀	88.1 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	192.2 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
HRPE	IC₅₀	1.6 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT2-expressing HRPE cells TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT2-expressing HRPE cells	[PMID: 9830022]
HRPE	IC₅₀	10.5 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT3-expressing HRPE cells TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT3-expressing HRPE cells	[PMID: 9830022]
HeLa	IC₅₀	> 50 6 Compound: 4	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24021891]
K562/R7	IC₅₀	10.6 3 Compound: progesterone	Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay	[PMID: 25634041]
LNCaP	IC₅₀	13.7 1 Compound: Progesterone	Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay	[PMID: 30925341]
NIH-3T3-G185	IC₅₀	192.2 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	88.1 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	96.2 3 Compound: Progesterone	TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells	[PMID: 11716514]
T47D	EC₅₀	0.1 1 Compound: P4	Activation of progesterone receptor in human T47D cells after 20 hrs by PRE-tagged luciferase reporter gene assay Activation of progesterone receptor in human T47D cells after 20 hrs by PRE-tagged luciferase reporter gene assay	[PMID: 19863083]
T47D	EC₅₀	0.9 1 Compound: 1	Activity at progesterone receptor assessed as alkaline phosphatase activity in human T47D cells Activity at progesterone receptor assessed as alkaline phosphatase activity in human T47D cells	[PMID: 18722119]
T47D	EC₅₀	0.9 1 Compound: P4 (Progesterone)	Effective concentration on alkaline phosphatase activity in human T47D breast carcinoma cell line. Effective concentration on alkaline phosphatase activity in human T47D breast carcinoma cell line.	[PMID: 12657271]
T47D	EC₅₀	0.92 1 Compound: P4	Agonistic activity against progesterone receptor in alkaline phosphatase assay using human T47D breast carcinoma cell line Agonistic activity against progesterone receptor in alkaline phosphatase assay using human T47D breast carcinoma cell line	[PMID: 11859003]
T47D	EC₅₀	1.8 1 Compound: Progesterone	Human progesterone receptor (hPR) agonist activity in T47D human breast cancer cell line Human progesterone receptor (hPR) agonist activity in T47D human breast cancer cell line	[PMID: 10743938]
T47D	EC₅₀	1.8 1 Compound: prog	Agonistic activity by cotransfection assay against human Progesterone receptor in T47D cells Agonistic activity by cotransfection assay against human Progesterone receptor in T47D cells	[PMID: 10212133]
T47D	EC₅₀	1.8 1 Compound: progesterone	Agonistic activity against human progesterone receptor in T47D breast cancer cells Agonistic activity against human progesterone receptor in T47D breast cancer cells	[PMID: 12954062]
T47D	EC₅₀	2.2 1 Compound: progesterone	Agonist activity at human progesterone receptor in human T47D cells assessed as alkaline phosphatase activity Agonist activity at human progesterone receptor in human T47D cells assessed as alkaline phosphatase activity	[PMID: 18553958]
T47D	IC₅₀	3.4 1 Compound: P4 (Progesterone)	Displacement of [3H]progesterone at progesterone receptor of T47D cells Displacement of [3H]progesterone at progesterone receptor of T47D cells	[PMID: 15081005]
T47D	IC₅₀	3.5 1 Compound: P4	Binding affinity for Progesterone receptor (PR) in human T47D breast carcinoma cells Binding affinity for Progesterone receptor (PR) in human T47D breast carcinoma cells	[PMID: 11859003]

In Vivo

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Progesterone can be used to create melasma models^[6].

Induction of Chloasma^[6]

Background

Progesterone increases the pigmentation and body weight. The body weight gain was believed to be due to sodium and fluid retention, which may further affect the intracellular pH of melanosomes, which synthesize melanin, in turn, leading to melanin production because tyrosinase activity is linked to the intracellular pH environment^[7].

Specific Modeling Methods

Mice: 6-8 weeks, female C57BL/6J mice
Administration: 15 mg/kg; Injected intramuscularly, daily for 30 days

Note

Selected 3*3 cm² area on the back of mice, shaved the hair, and then irradiated with UVB (λ=312 nm, 2 h/day).

Modeling Indicators

Phenotypic changes: cutaneous tissue injury, scab format, skin got blacker. Tissue changes: hair follicles necrosis, fibrous tissue hyperplasia, epidermal melanocyte enrichment. Molecular changes: p-JNK /JNK, p-P38MAPK/P38MAPK ↑.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult female mice (7-13 wk, 18-28 g)^[4]
Dosage:	1 mg
Administration:	Injections; three consecutive daily
Result:	Stimulated vessel maturation in the mouse endometrium.

Peso molecular

314.46

Fòrmula

C₂₁H₃₀O₂

No. CAS

57-83-0

Appearance

Solid

Color

White to off-white

SMILES

CC([C@H]1CC[C@@]2([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O)=O

Initial Source

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvente y solubilidad

In Vitro:

DMSO : 50 mg/mL (159.00 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.1801 mL	15.9003 mL	31.8005 mL
5 mM	0.6360 mL	3.1801 mL	6.3601 mL
10 mM	0.3180 mL	1.5900 mL	3.1801 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (6.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil
Solubility: 10 mg/mL (31.80 mM); Clear solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 20 mg/mL (63.60 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureza y Documentación

Purity: 99.79%

Select Batch:

Ficha de datos (283 KB) SDS (418 KB)

COA (252 KB) HNMR (273 KB) RP-HPLC (245 KB) LCMS (93 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Schindler AE, et al. Classification and pharmacology of progestins. Maturitas. 2003 Dec 10;46 Suppl 1:S7-S16. [Content Brief]

[2]. Zava DT, et al. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med. 1998 Mar;217(3):369-78. [Content Brief]

[3]. Komesaroff PA, et al. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric. 2001 Jun;4(2):144-50. [Content Brief]

[4]. Girling JE, et al. Progesterone, but not estrogen, stimulates vessel maturation in the mouse endometrium. Endocrinology. 2007 Nov;148(11):5433-41. Epub 2007 Aug 9. [Content Brief]

[5]. Wong R, et al. Progesterone pharmacokinetics in the mouse: implications for potential stroke therapy. J Pharm Pharmacol. 2012 Nov;64(11):1614-20. [Content Brief]

[6]. Wang JY, et al. Licorice zinc suppresses melanogenesis via inhibiting the activation of P38MAPK and JNK signaling pathway in C57BL/6J mice skin. Acta Cir Bras. 2022 Dec 19;37(10):e371002. [Content Brief]

[7]. Hisayoshi NoRIMOTO, et al. Effects of keishibukuryoganryokayokuinin (gui-zhi-fu-ling-wanliao-jia-yiyiren) on the Epidermal Pigment Cells from DBA/2 Mice Exposed to Ultraviolet B (UVB) and/or Progesterone. The pharmaceutical Society of Japan. 2011, 131(11):1613-1619.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.1801 mL	15.9003 mL	31.8005 mL	79.5014 mL
	5 mM	0.6360 mL	3.1801 mL	6.3601 mL	15.9003 mL
	10 mM	0.3180 mL	1.5900 mL	3.1801 mL	7.9501 mL
	15 mM	0.2120 mL	1.0600 mL	2.1200 mL	5.3001 mL
	20 mM	0.1590 mL	0.7950 mL	1.5900 mL	3.9751 mL
	25 mM	0.1272 mL	0.6360 mL	1.2720 mL	3.1801 mL
	30 mM	0.1060 mL	0.5300 mL	1.0600 mL	2.6500 mL
	40 mM	0.0795 mL	0.3975 mL	0.7950 mL	1.9875 mL
	50 mM	0.0636 mL	0.3180 mL	0.6360 mL	1.5900 mL
	60 mM	0.0530 mL	0.2650 mL	0.5300 mL	1.3250 mL
	80 mM	0.0398 mL	0.1988 mL	0.3975 mL	0.9938 mL
	100 mM	0.0318 mL	0.1590 mL	0.3180 mL	0.7950 mL

Progesterone Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Progesterone57-83-0Pregn-4-ene-3,20-dioneProgesterone ReceptorEndogenous MetaboliteNR3C3Inhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Nombre del producto			Requested Quantity *
Nombre del solicitante *			Saludo
Direcciòn del E-mail *			Número de teléfono *
Department			Nombre de la Organizaciòn *
City			Provincia
Country or Region *
Observaciones

Nombre del producto			Lot #
Nombre del solicitante *			Direcciòn del E-mail *
Número de teléfono			Department *
Nombre de la Organizaciòn *			Country or Region *
Observaciones

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

Progesterone (Synonyms: Pregn-4-ene-3,20-dione)

Revisión del cliente

Other Forms of Progesterone:

Progesterone Related Antibodies

34 Publications Citing Use of MCE Progesterone

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas Endogenous Metabolite:

Actividad biológica

Pureza y Documentación

Referencias

Revisión del cliente

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

Progesterone Related Classifications

Keywords:

Productos vistos recientemente:

Revisión del cliente

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report